Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT02220738 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
19
Enrollment
INDUSTRY
Sponsor class

Stopped Slow subject enrollment

Conditions

Interventions

Sponsor

AbbVie